ImmunityBio (IBRX) Return on Sales (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Return on Sales data on file, last reported at 0.14% in Q1 2026.

• On a quarterly basis, Return on Sales fell 6.0% year-over-year to 0.14% in Q1 2026; TTM through Mar 2026 was 0.06%, a 7.0% increase from a year earlier, with the FY2025 full-year figure at 0.03%, up 25.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.14%, down from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for IBRX reached as high as 0.02% in Q4 2025 and fell as low as 73.57% in Q1 2022.
• Historically, Return on Sales has averaged 13.27% across 5 years, with a median of 3.24% in 2023.
• Across the five-year window, Return on Sales slumped 6778 bps in 2022 and jumped 7033 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 14.84% in 2022, then retreated by 13 bps to 16.79% in 2023, then soared by 100 bps to 0.08% in 2024, then surged by 79 bps to 0.02% in 2025, then plunged by 785 bps to 0.14% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.14% in Q1 2026, 0.02% in Q4 2025, and 0.02% in Q3 2025.